Table 1.
Clinical and demographic characteristics of enrolled subjects.
| Demographic/Clinical Data | Healthy Controls n = 10 |
Ulcerative Colitis Patients | ||
|---|---|---|---|---|
| Responders n = 13 |
Steroid-Refractory n = 4 |
Steroid-Dependent n = 4 |
||
| Gender (n; %) Male Female |
5 (50) 5 (50) |
6 (46) 7 (54) |
2 (50) 2 (50) |
1 (25) 3 (75) |
| Age in years (median; range) | 53 (41–66) | 32 (20–63) | 29 (22–38) | 38 (24–41) |
| Body mass index (median; range) | 26 (20.7–29.8) | 24.1 (16.9–29.8) | 22 (14.7–32.1) | 21 (18–26.3) |
| Smoking habit (n; %) | 1 (10) | 1 (8) | 1 (25) | 1 (25) |
| Family history of IBD (n; %) | 0 (0) | 2 (15) | 0 (0) | 1 (25) |
| Years of disease (median; range) | - | 1 (0–8) | 1 (1–2) | 8 (3–20) |
| Extraintestinal manifestations (n; %) | - | 5 (38) | 0 (0) | 3 (75) |
| Montreal classification (n; %) E1: Extensive colitis E2: Left-sided colitis E3: Proctitis |
- |
11 (85) 2 (15) 0 (0) |
3 (75) 1 (25) 0 (0) |
3 (75) 1 (25) 0 (0) |
| IBD current treatment (n; %) 5—Aminosalicylates Azathioprine Methotrexate 6-Mercaptopurine |
- |
9 (69) 2 (15) 1 (8) 1 (8) |
4 (100) 0 (0) 0 (0) 0 (0) |
2 (50) 2 (50) 0 (0) 0 (0) |
| Clinical Mayo score (median; range) | - | 4 (1–8) | 4 (2–7) | 5 (3–5) |
| Endoscopic Mayo score 2 (Moderate activity) 3 (Severe activity) |
- |
9 (69) 4 (31) |
2 (50) 2 (50) |
3 (75) 1 (25) |
| Fecal calprotectin (median; range) | - | 939 (254–2410) | 600 (258–1320) | 640 (600–1200) |